Bristol Myers Squibb (BMY) Operating Expenses (2009 - 2026)

Bristol Myers Squibb (BMY) has 18 years of Operating Expenses data on file, last reported at $8.2 billion in Q1 2026.

• Operating Expenses for Q1 2026 came in at $8.2 billion, changed 0.24% year-over-year; the trailing twelve-month figure through Mar 2026 was $38.9 billion (down 6.36% YoY), and the FY2025 annual result was $38.9 billion, down 31.43% from the prior year.
• Operating Expenses slipped to $8.2 billion in Q1 2026 per BMY's latest filing, from $11.0 billion in the prior quarter.
• Over five years, Operating Expenses peaked at $23.4 billion in Q1 2024 and troughed at $8.2 billion in Q1 2025.
• A 5-year average of $10.5 billion and a median of $9.8 billion in 2023 frame the typical range for Operating Expenses.
• The sharpest annual moves came in 2024 and 2025: Operating Expenses soared 172.92% in 2024, then sank 64.8% in 2025.
• A 5-year view of Operating Expenses shows it stood at $9.5 billion in 2022, then advanced by 2.68% to $9.8 billion in 2023, then grew by 24.12% to $12.2 billion in 2024, then declined by 9.33% to $11.0 billion in 2025, then declined by 25.22% to $8.2 billion in 2026.
• Business Quant data shows BMY's Operating Expenses at $8.2 billion in Q1 2026, $11.0 billion in Q4 2025, and $9.1 billion in Q3 2025.